Search Results

controls. 205 , 206 During community outbreaks, influenza infections may represent a significant proportion of episodes of febrile neutropenia. 207 Influenza infections in severely immunocompromised patients with cancer are often associated with

: implication and proposed mechanisms . World J Clin Oncol 2014 ; 5 : 272 – 282 . 10.5306/wjco.v5.i3.272 25114844 23. Kuderer NM , Dale DC , Crawford J , . Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients

arms (86% and 85% for ibrutinib + obinutuzumab and chlorambucil + obinutuzumab, respectively). Pneumonia (5%), atrial fibrillation (4%), febrile neutropenia (4%), and pyrexia (4%) were the most common adverse events in the ibrutinib + obinutuzumab arm

treatment-related grade 1/2 adverse events. Incidence of grade 3/4 febrile neutropenia and anemia were reported in 5% and 20% of patients, respectively. In a phase II study of 25 patients (16 with relapsed CLL and 9 with Richter's transformation to DLBCL

-stimulating factor use without an increase in febrile neutropenia rates, illustrating the positive impact these powerful tools can have on clinical oncology care. 50 Further analyses of the use of these tools with appropriate study designs and analytic methods are

compared with those only receiving ADT and docetaxel. The populations receiving the triplet and doublet therapies experienced similar rates of neutropenia, febrile neutropenia, fatigue, and neuropathy, although grade ≥3 adverse events occurred 63% of

prophylaxis with granulocyte-colony stimulating factors (G-CSF) versus placebo or untreated controls in patients undergoing chemotherapy indicated that G-CSF therapy was associated with decreased incidences of febrile neutropenia and early death, and a higher

, comorbidities, anthracycline-based regimens, a 28-day schedule, and febrile neutropenia as independent predictors of reduced dose-intensity among patients with early-stage breast cancer undergoing adjuvant chemotherapy. 167 In another retrospective analysis of

CR and 5% achieved a partial response (PR), with median response duration of 98 months for all responders. The most common toxicities were neutropenia (grade 3/4; occurring in ≈65%–85%), febrile neutropenia (40%), thrombocytopenia (grade 3/4; 20

chemotherapy with a high rate of febrile neutropenia. 9 Table 2 displays the benefits and potential risks of parenteral iron administration reported in a variety of patient populations or studied in animal models. Because these risks have not specifically